Mia-Louise Nielsen

Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level.

T. Petersen, L. Skov, J. Thyssen, 2022, JAMA dermatology.

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.

L. Skov, J. Thyssen, M. Rasmussen, 2022, Seminars in arthritis and rheumatism.

Delay in diagnosis and treatment of patients with psoriasis: a population‐based cross‐sectional study

J. Thyssen, A. Egeberg, S. Thomsen, 2022, The British journal of dermatology.

The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study

J. Thyssen, J. Maul, J. Thorsen, 2022, The British journal of dermatology.

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

L. Skov, M. Gyldenløve, C. Zachariae, 2023, The Lancet regional health. Europe.

Acceptance of telemedicine compared to in-person consultation from the providers and users’ perspectives: A multicenter, cross-sectional study in dermatology (Preprint)

A. Navarini, J. Maul, M. Streit, 2023, JMIR Dermatology.

Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis - a nationwide cohort study.

L. Skov, J. Thyssen, M. Rasmussen, 2023, Journal of the American Academy of Dermatology.